BACKGROUND: The Amblyopia Treatment Index (ATI) is a parental questionnaire that has been used to assess the impact of patching or atropine treatment on the child and family in several amblyopia treatment studies. The 18-item parental questionnaire was designed with versions for treatment with patching or atropine. We pooled data across studies to further evaluate the validity of the ATI, to further assess the presence or absence of factors (subscales). METHODS: A parent or guardian completed the ATI for 794 children who participated in 1 of 4 randomized clinical trials. Internal consistency reliability was assessed with Cronbach's alpha, and factor analysis was performed. RESULTS: The ATI demonstrated high internal consistency reliability, with a Cronbach's alpha of 0.88 (95% CL = 0.87, 0.89). Factor analysis revealed the same 3 minimally overlapping factors found in the original validation study, which were again labeled "adverse effects," "treatment compliance," and "social stigma." Two of the 18 items did not load with any factor and could reasonably be omitted from future ATI administrations. CONCLUSIONS: The ATI is a useful instrument for assessing the impact of patching or atropine treatment on the child and family.
BACKGROUND: The Amblyopia Treatment Index (ATI) is a parental questionnaire that has been used to assess the impact of patching or atropine treatment on the child and family in several amblyopia treatment studies. The 18-item parental questionnaire was designed with versions for treatment with patching or atropine. We pooled data across studies to further evaluate the validity of the ATI, to further assess the presence or absence of factors (subscales). METHODS: A parent or guardian completed the ATI for 794 children who participated in 1 of 4 randomized clinical trials. Internal consistency reliability was assessed with Cronbach's alpha, and factor analysis was performed. RESULTS: The ATI demonstrated high internal consistency reliability, with a Cronbach's alpha of 0.88 (95% CL = 0.87, 0.89). Factor analysis revealed the same 3 minimally overlapping factors found in the original validation study, which were again labeled "adverse effects," "treatment compliance," and "social stigma." Two of the 18 items did not load with any factor and could reasonably be omitted from future ATI administrations. CONCLUSIONS: The ATI is a useful instrument for assessing the impact of patching or atropine treatment on the child and family.
Authors: P S Moke; A H Turpin; R W Beck; J M Holmes; M X Repka; E E Birch; R W Hertle; R T Kraker; J M Miller; C A Johnson Journal: Am J Ophthalmol Date: 2001-12 Impact factor: 5.258
Authors: J M Holmes; R W Beck; M X Repka; D A Leske; R T Kraker; R C Blair; P S Moke; E E Birch; R A Saunders; R W Hertle; G E Quinn; K A Simons; J M Miller Journal: Arch Ophthalmol Date: 2001-09
Authors: S R Cole; R W Beck; P S Moke; M P Celano; C D Drews; M X Repka; J M Holmes; E E Birch; R T Kraker; K E Kip Journal: J AAPOS Date: 2001-08 Impact factor: 1.220
Authors: Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace Journal: Ophthalmology Date: 2004-11 Impact factor: 12.079
Authors: Jonathan M Holmes; Raymond T Kraker; Roy W Beck; Eileen E Birch; Susan A Cotter; Donald F Everett; Richard W Hertle; Graham E Quinn; Michael X Repka; Mitchell M Scheiman; David K Wallace Journal: Ophthalmology Date: 2003-11 Impact factor: 12.079
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: Jonathan M Holmes; Roy W Beck; Raymond T Kraker; Stephen R Cole; Michael X Repka; Eileen E Birch; Joost Felius; Stephen P Christiansen; David K Coats; Marjean T Kulp Journal: Arch Ophthalmol Date: 2003-11
Authors: Joost Felius; Danielle L Chandler; Jonathan M Holmes; Raymond H Chu; Stephen R Cole; Michael Hill; Kristine Huang; Marjean Taylor Kulp; Elizabeth L Lazar; Noelle S Matta; Michele Melia; David K Wallace Journal: J AAPOS Date: 2010-10 Impact factor: 1.220
Authors: Tina Y Gao; Cindy X Guo; Raiju J Babu; Joanna M Black; William R Bobier; Arijit Chakraborty; Shuan Dai; Robert F Hess; Michelle Jenkins; Yannan Jiang; Lisa S Kearns; Lionel Kowal; Carly S Y Lam; Peter C K Pang; Varsha Parag; Roberto Pieri; Rajkumar Nallour Raveendren; Jayshree South; Sandra Elfride Staffieri; Angela Wadham; Natalie Walker; Benjamin Thompson Journal: JAMA Ophthalmol Date: 2018-02-01 Impact factor: 7.389
Authors: Robert P Rutstein; Graham E Quinn; Elizabeth L Lazar; Roy W Beck; Dean J Bonsall; Susan A Cotter; Eric R Crouch; Jonathan M Holmes; Darren L Hoover; David A Leske; Ingryd J Lorenzana; Michael X Repka; Donny W Suh Journal: Ophthalmology Date: 2010-02-16 Impact factor: 12.079